VEGFA and head and neck squamous cell carcinoma: The use of VEGF-TKIs in other solid organ tumors has been promising and may suggest further study for the use of anti-angiogenic therapies in SCCHN, either as monotherapy or in combination with immune checkpoint inhibitors, two of which are currently approved for use in SCCHN.